CT-INTERACTIVE-BROKERS
Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced the launch of Traders’ Insight Radio , a new podcast series featuring interviews with executives, thought leaders and market experts from across the financial services industry discussing topical themes impacting global markets and trading. Listeners familiar with Traders’ Insight , Interactive Brokers’ online resource for market commentary, will recognize in-house IBKR podcast hosts providing important context around the singular viewpoints being examined during the conversations.
Intended for a broad audience including both advanced traders and novice investors, Traders’ Insight Radio explores a wide range of interesting topics for any investor and enhances the suite of offerings already available through IBKR Campus , the company’s best-in-class educational resource. Recent and upcoming podcasts will feature conversations on the impact of artificial intelligence (AI) on markets, opportunities in foreign securities and views on cryptocurrency as the new digital asset class. For retail investors just starting out or advanced traders seeking to expand their knowledge base, IBKR Campus includes courses and content on trading, markets and current events, as well as overviews dedicated to IBKR’s products and trading platforms – and now, notable podcast interviews.
“We continue to focus on providing investors with the educational tools needed to improve their understanding of financial markets and trading,” said Steve Sanders, EVP of Marketing and Product Development at Interactive Brokers. “Traders’ Insight Radio complements the resources already available through IBKR Campus and is a new and entertaining way all investors can easily access and benefit from expertise across the finance industry.”
The series was introduced in January and early episodes include a two-part interview with Thomas Peterffy, Founder and Chairman of Interactive Brokers Group, discussing his early trading days as an options market maker and how he successfully introduced technology to the trading floor. Listeners will benefit from Mr. Peterffy’s perspective on a variety of subjects such as cryptocurrency, monetary policy and the impact of rising rates and inflation on the economy, while hearing anecdotes from his storied career. To listen to Mr. Peterffy’s podcast interviews, please visit:
Part 1: "You Mean You Don't Have to Know Anything to Do This?"
Part 2: "Mr. Sosnick, I Do Find You Increasingly Useless"
The latest episodes of Traders’ Insight Radio are available for free on the Traders’ Insight blog, through Interactive Brokers’ trading platforms including Trader Workstation, Client Portal and IBKR Mobile and popular podcasting services including Apple Podcast, Google Podcast, Podbean and Spotify.
For the full suite of free IBKR Campus resources, please see below and visit ibkr.com/campus .
Traders' Academy : Investors can improve their understanding of the products, tools and markets available through Interactive Brokers’ Trader Workstation, Client Portal, IBKR Mobile and TWS API applications.
IBKR Webinars : Investors can watch, listen and learn about current market topics and IBKR tools through live and recorded webinars.
Traders' Insight : Investors can watch, read or listen to market commentary from more than 70 industry professionals, including the new Traders’ Insight Radio.
IBKR Quant : A blog intended for quantitative professionals with an interest in programming, deep learning, IBKR API, AI, Blockchain and other transformative technologies influencing modern markets.
Student Trading Lab : A free online resource for educators looking to blend finance or computer science classwork with real-world trading experience.
About Interactive Brokers Group, Inc.:
Interactive Brokers Group affiliates provide automated trade execution and custody of securities, commodities and foreign exchange around the clock on over 135 markets in numerous countries and currencies, from a single IBKR Integrated Investment Account to clients worldwide. We service individual investors, hedge funds, proprietary trading groups, financial advisors and introducing brokers. Our four decades of focus on technology and automation has enabled us to equip our clients with a uniquely sophisticated platform to manage their investment portfolios. We strive to provide our clients with advantageous execution prices and trading, risk and portfolio management tools, research facilities and investment products, all at low or no cost, positioning them to achieve superior returns on investments. Barron’s ranked Interactive Brokers #1 with 5 out of 5 stars in its February 26, 2021, Best Online Broker Review.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220223006298/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom